Novel iontophoretic administration method for local therapy of breast cancer

Journal of Controlled Release

Volumn 168, Issue 3, 2013, Pages 298-306

  Komuro, Masahito ^a   Suzuki, Kenichi ^b   Kanebako, Makoto ^b   Kawahara, Takashi ^c   Otoi, Takeshige ^c   Kitazato, Kenji ^a,f   Inagi, Toshio ^b   Makino, Kimiko ^d   Toi, Masakazu ^e   Terada, Hiroshi ^d  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b KOWA COMPANY LTD   (Japan)

^c YAMAGUCHI UNIVERSITY   (Japan)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

^e KYOTO UNIVERSITY HOSPITAL   (Japan)

^f Kurume Research Center   (Japan)

Author keywords

Drug delivery system; Ductal carcinoma in situ; Iontophoresis; Milk duct; Miproxifen; Primary breast cancer

Indexed keywords

BREAST CANCER; DRUG DELIVERY SYSTEM; DUCTAL CARCINOMA IN SITU; IONTOPHORESIS; MIPROXIFEN;

DRUG DELIVERY; DRUG DOSAGE; DUCTS; ELECTROPHORESIS; ELECTROTHERAPEUTICS; RADIOGRAPHY;

DISEASES;

ANTINEOPLASTIC AGENT; DP TAT 59; DRUG METABOLITE; MIPROXIFENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPLICATION SITE IRRITATION; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; BREAST CANCER; BREAST DUCT; CANCER THERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; FEMALE; IONTOPHORESIS; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SKIN PENETRATION; SYSTEMIC THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOGS; DRUG DELIVERY SYSTEMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IONTOPHORESIS; MAMMARY GLANDS, ANIMAL; RATS; TAMOXIFEN;

EID: 84877041578     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.03.021     Document Type: Article

References (26)

1. D.M. Parkin, and L.M.G. Fernandez Use of Statistics to Assess the Global Burden of Breast Cancer Breast J. 12 2006 S70 S80
2. V. Espina, and L.A. Liotta What is the malignant nature of human ductal carcinoma in situ Nat. Rev. Cancer 11 2011 68 75
3. C.J. Allegra, D.R. Aberle, P. Ganschow, S.M. Hahn, C.N. Lee, S. Millon-Underwood, M.C. Pike, S.D. Reed, A.F. Saftlas, S.A. Scarvalone, A.M. Schwartz, C. Slomski, G. Yothers, and R. Zon National institutes of health state-of-the science conference statement: Diagnosis and management of ductal carcinoma in situ September 22-24,2009 J. Natl. Cancer. Ins. 102 2010 161 169
4. W. Wu, H. Kamma, E. Ueno, M. Fujiwara, H. Satoshi, H. Hara, T. Yashiro, and Y. Aiyoshi The intraductal component of breast cancer is poorly responsive to neo-adjuvant chemotherapy Oncol. Rep. 9 2002 1027 1031
5. C. Mazouni, F. Peintinger, S. Wan-Kau, F. Andre, A.M. Gonzalez-Angulo, W.F. Symmans, F. Meric-Bernstam, V. Valero, G.N. Hortobagyi, and L. Pusztai Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome J. Clin. Oncol. 25 2007 2650 2655
6. S. Murata, S.L. Kominsky, M. Vali, Z. Zhang, E. Garrett-Mayer, D. Korz, D. Huso, S.D. Baker, J. Barber, E. Jaffee, R.T. Reilly, and S. Sukumar Ductal access for prevention and therapy of mammary tumors Cancer Res. 66 2006 638 645
7. J. Rao, H. Yang, B. Zhang, W. Zhang, and S. Love Histopathological responses to a short term intraductal cytotoxic agent treatment: results of a feasibility study BMC Proc. 3 Suppl. 5 2009 S30
8. S.M. Love, B. Zhang, W. Zhang, B. Zhang, H. Yang, and J. Rao Local drug delivery to the breast: a phase 1 study of breast cytotoxic agent administration prior to mastectomy BMC Proc. 3 Suppl. 5 2009 S29
9. M. Flanagan, S. Love, and E.S. Hwang Status of intraductal therapy for ductal carcinoma in situ Curr. Breast. Cancer. Rep. 2 2010 75 82
10. P. Singh, P. Liu, and S.M. Dinh Facilitated transdermal delivery by iontophoresis R.L. Bronaugh, H.I. Maibach, Percutaneous Absorptio Drugs-Cosmetics-Mechanisms-Methodology 3rd ed. 1998 Marcel Dekker Inc. New York 633 657
11. A. Alexander, S. Dwivedi, T.K. Giri Ajazuddin, S. Saraf, S. Saraf, and D.K. Tripathi Approaches for breaking the barriers of drug permeation through transdermal drug delivery J. Control. Release 164 2012 26 40
12. N.K. Brogden, M. Milewski, P. Ghosh, L. Hardi, L.J. Crofford, and A.L. Stinchcomb Diclofenac delays micropore closure following microneedle treatment in human subject J. Control. Release 163 2012 220 229
13. T. Toko, Y. Sugimoto, K. Matsuo, R. Yamasaki, S. Takeda, K. Wierzba, T. Asao, and Y. Yamada TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors Eur. J. Cancer 26 1990 397 404
14. N.L. Barnes, G.P. Boland, A. Davenport, W.F. Knox, and N.J. Bundred Relationship between hormone receptor status and tumor size, grade and comedo necrosis in ductal carcinoma in situ Br. J. Surg. 92 2005 429 434
15. K. Ikeda, M. Nagamachi, H. Masuda, S. Nagayama, and Y. Kawaguchi Metabolic fate of TAT-59 (third report)-Absorption and Metabolism of TAT-59 Jpn. Pharmacol. Ther. 26 1998 797 807
16. J. Shibata, T. Toko, H. Sato, A. Fujioka, K. Sato, A. Hashimoto, K. Wierzba, and Y. Yamada Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59) Cancer Chemother. Pharmacol. 45 2000 133 141
17. Y. Nomura, O. Abe, K. Enomono, K. Fujiwara, T. Tominaga, K. Hayashi, J. Uchino, M. Takahashi, A. Hayasaka, K. Asaishi, M. Okazaki, R. Abe, I. Kimishima, T. Kajiwara, S. Haga, T. Shimizu, I. Miyazaki, M. Noguchi, M. Yoshida, S. Miura, T. Taguchi, J. Oota, K. Sakai, H. Kinoshita, T. Morimoto, Y. Monden, T. Morimoto, M. Komaki, and H. Tashiro Phase I study of TAT-59 (a new antiestrogen) in breast cancer Jpn. J. Cancer Chemother. 25 1998 553 561
18. H. Aoyama, T. Tominaga, and O. Abe Early phase II study of TAT-59 in patients with advanced or recurrent breast cancer-a multicenter dose finding study Jpn. J. Cancer Chemother. 25 1998 853 865
19. Y. Nomura, M. Nakajima, T. Tominaga, and O. Abe Late phase II study of TAT-59 (miproxifene phosphate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate) Jpn. J. Cancer Chemother. 25 1998 1045 1063
20. A.J. Bailer Testing for the equality of area under the curves when using destructive measurement techniques J. Pharmacokinet. Biopharm. 16 1988 303 309
21. M. Hutteman, J.S. Mieog, J.R. van der Vorst, G.J. Liefers, H. Putter, C.W. Lowik, J.V. Frangioni, C.J. van de Velde, and A.L. Vahrmeijer Randomized, double-blind comparison of indocyanine green with or without albumin premixing for near-infrared fluorescence imaging of sentinel lymph nodes in breast cancer patients Breast Cancer Res. Treat. 127 2011 163 170
22. M.E. Miller Anatomy of the dog 1964 W.B. Saunders Company Philadelphia
23. 14C-TAT-59 after oral administration to rats Jpn. Pharmacol. Ther. 26 1998 485 509
24. C. Curdy, Y.N. Kalia, and R.H. Guy Non-invasive assessment of the effect of iontophoresis on human skin in-vivo J. Pharm. Pharmacol. 53 2001 769 777
25. R. van der Geest, D.A.R. Elshove, M. Danhof, A.P.M. Lavrijsen, and H.E. Bodde Non-invasive assessment of skin barrier integrity and skin irritation following iontophoretic current application in humans J. Control Release. 41 1996 205 213
26. J. Singh, M. Gross, B. Sage, H.T. Davis, and H.I. Maibach Regional variations in skin barrier function and cutaneous irritation due to iontophoresis in human subjects Food Chem. Toxicol. 39 2001 1079 1086